Oncotarget

Meta-Analysis:

Antihypertensive drug use and breast cancer risk: a meta-analysis of observational studies

Haibo Ni, Qin Rui, Xiaojue Zhu, Zhenquan Yu, Rong Gao and Huixiang Liu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:62545-62560. https://doi.org/10.18632/oncotarget.19117

Metrics: PDF 773 views  |   HTML 1742 views  |   ?  


Abstract

Haibo Ni1,*, Qin Rui2,*, Xiaojue Zhu2,*, Zhenquan Yu3, Rong Gao1 and Huixiang Liu1

1Department of Neurosurgery, The First People’s Hospital of Zhangjiagang City, Suzhou, Jiangsu, China

2Department of Laboratory, The First People’s Hospital of Zhangjiagang City, Suzhou, Jiangsu, China

3Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

*These authors have contributed equally to this work

Correspondence to:

Huixiang Liu, email: zjg_lhx@163.com

Rong Gao, email: tsong@vip.sina.com

Keywords: antihypertensive drug, breast cancer, meta-analysis, cancer prevention, epidemiology

Received: July 20, 2016    Accepted: April 14, 2017    Published: July 10, 2017

ABSTRACT

We conducted a meta-analysis of observational studies to examine the hypothesized association between breast cancer and antihypertensive drug (AHT) use. Fixed- or random- effect models were used to calculate pooled risk ratios (RRs) and 95% confidence intervals (CIs) for all AHTs and individual classes (i.e., angiotensin-converting enzyme inhibitors, [ACEi]; angiotensin-receptor blockers, [ARBs]; calcium channel blockers, [CCBs]; beta-blockers, [BBs], and diuretics). Twenty-one studies with 3,116,266 participants were included. Overall, AHT use was not significantly associated with breast cancer risk (RR = 1.02, 95% CI: 0.98-1.06), and no consistent association was found for specific AHT classes with pooled RRs of 1.02 (95% CI: 0.96-1.09) for BBs, 1.07 (95% CI: 0.99-1.16) for CCBs, 0.99 (95% CI: 0.93-1.05) for ACEi/ARBs, and 1.05 (95% CI: 0.99-1.12) for diuretics. When stratified by duration of use, there was a significantly reduced breast cancer risk for ACEi/ARB use ≥10 years (RR = 0.80, 95% CI: 0.67-0.95). Although there was no significant association between AHT use and breast cancer risk, there was a possible beneficial effect was found for long-term ACEi/ARB. Large, randomized controlled trials with long-term follow-up are needed to further test the effect of these medications on breast cancer risk.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19117